Home » Newsletters » BioWorld Science

BioWorld Science

March 22, 2007

View Archived Issues

Combining tiotropium and fluticasone-salmeterol beneficial in COPD

AM-111 otoprotective in acute labyrinthitis model

Diverse immune responses seen with full-length p53 antigen-expressing vaccine

Myxoma virus: A novel viral oncolytic approach in hard to treat cancers

Targeted nanoparticles found effective in premalignant epithelial neoplasia

Interferon/gemcitabine-based adjuvant therapy improves survival, toxicity remains a concern

Zogenix closes USD 10 million financing deal

Enrollment completed in phase III Alzheimer's trial of Flurizan

CUV-1647 to be studied for prevention of phototoxicity in PDT

SPA filing for phase III study of Xyotax plus carboplatin in women with NSCLC

Pain Therapeutics cleared for Israeli phase I metastatic melanoma study

New data suggest utility of Homspera as cotherapeutic agent

Dharma's IDDS effective in reducing pain in phase II study

Updated interim antibody reduction data reported for Riquent

Cannasat and IntelGenx to codevelop novel cannabinoid-based product

Combination studies with sorafenib to continue after positive findings

Radius' hPTHrP analogue begins phase II testing for osteoporosis

Enrollment open in phase I/II study of plasmin for acute PAO

Potential applications for Unigene's site-directed bone growth technology

GenVec and NIAID sign CRADA for RSV vaccine development

Pharmatek to manufacture ANX-201 for clinical studies

No causal link between neuropsychiatric symptoms and treatment with Tamiflu

Aquavan provides successful sedation in patients undergoing bronchoscopy

Japanese approval for Risperdal OD

Novel agents are reported for use in the treatment of genitourinary disorders

Novel treatments for psychological disorders claimed in recent patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...